WBRT Plus SIB in Patients with Brain Metastases: Association with Longer Overall Survival and Safety Outcomes in a Single-Center Retrospective Analysis
- 1Department of Radiation Oncology, Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology, The Second Clinical Medical College, Jinan University), Shenzhen 518020, China
Abstract
Objective: To compare the efficacy, survival benefits, and safety of whole-brain radiotherapy (WBRT) alone versus WBRT combined with simultaneous integrated boost (WBRT+SIB) for patients with brain metastases. Methods: A total of 100 patients treated from 2017 to 2022 were retrospectively analyzed. Tumor response was assessed per RECIST 1.1. Survival differences were compared using the Kaplan–Meier method and log-rank test. Multivariate Cox regression and subgroup analyses were performed to evaluate the prognostic value and stability of WBRT+SIB. Results: The WBRT+SIB group exhibited numerically higher objective response and disease control rates without statistical significance. With a median follow-up of 31.0 months, WBRT+SIB significantly prolonged median overall survival (11.0 vs. 8.0 months, p = 0.011) and improved 1-, 2-, and 3-year survival rates. After adjusting for multiple confounders, WBRT+SIB independently reduced mortality risk (HR = 0.51, 95% CI: 0.27–0.97, p = 0.039). Subgroup analyses were exploratory; therefore, consistent survival advantages across strata cannot be confirmed. No significant differences in acute, subacute, or late neurotoxicity, including radiation-induced brain necrosis, were found between the two groups. Conclusions: WBRT+SIB was associated with longer overall survival compared with WBRT alone, without a significant increase in the incidence of radiotherapy-related adverse events. Although ORR and DCR were numerically higher in the WBRT+SIB group, these differences were not statistically significant. Given the limitations of this exploratory study, these findings should be considered hypothesis-generating and require validation in prospective randomized trials.
Related
- Peripheral immune-inflammatory markers associated with intracranial progression-free survival after Gamma Knife radiosurgery in patients with non-small cell lung cancer brain metastases: a retrospective cohort study.
- Pretreatment Body Composition and Its Association with Pathologic Complete Response and Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Retrospective Cohort Study
- Clinical Performance and Survival Outcomes of All-on-4 Full-Arch Implant-Supported Prostheses in Patients With a Completely Edentulous Arch: A Retrospective Cohort Study
- The Effect of Fine (PM2.5) and Coarse (PM10-2.5) Particulate Matter on Survival Outcomes in Nasopharyngeal Carcinoma Patients: A Retrospective Cohort Study in a Northern Thailand Tertiary Care Center.
- Real-World Management and Survival Outcomes in Patients with Primary or Recurrent Retroperitoneal Liposarcoma: A Single-Center Retrospective Cohort Study
BibTeX
@article{tang2026wbrt,
title = {{WBRT Plus SIB in Patients with Brain Metastases: Association with Longer Overall Survival and Safety Outcomes in a Single-Center Retrospective Analysis}},
author = {Zibo Tang and Guixiang Liao and Juan Fan},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203320},
url = {https://www.mdpi.com/2072-6694/18/20/3320},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - WBRT Plus SIB in Patients with Brain Metastases: Association with Longer Overall Survival and Safety Outcomes in a Single-Center Retrospective Analysis
AU - Zibo Tang
AU - Guixiang Liao
AU - Juan Fan
PY - 2026
DA - 2026/10/15
JO - Cancers
DO - 10.3390/cancers18203320
UR - https://www.mdpi.com/2072-6694/18/20/3320
AB - Objective: To compare the efficacy, survival benefits, and safety of whole-brain radiotherapy (WBRT) alone versus WBRT combined with simultaneous integrated boost (WBRT+SIB) for patients with brain metastases. Methods: A total of 100 patients treated from 2017 to 2022 were retrospectively analyzed. Tumor response was assessed per RECIST 1.1. Survival differences were compared using the Kaplan–Meier method and log-rank test. Multivariate Cox regression and subgroup analyses were performed to evaluate the prognostic value and stability of WBRT+SIB. Results: The WBRT+SIB group exhibited numerically higher objective response and disease control rates without statistical significance. With a median follow-up of 31.0 months, WBRT+SIB significantly prolonged median overall survival (11.0 vs. 8.0 months, p = 0.011) and improved 1-, 2-, and 3-year survival rates. After adjusting for multiple confounders, WBRT+SIB independently reduced mortality risk (HR = 0.51, 95% CI: 0.27–0.97, p = 0.039). Subgroup analyses were exploratory; therefore, consistent survival advantages across strata cannot be confirmed. No significant differences in acute, subacute, or late neurotoxicity, including radiation-induced brain necrosis, were found between the two groups. Conclusions: WBRT+SIB was associated with longer overall survival compared with WBRT alone, without a significant increase in the incidence of radiotherapy-related adverse events. Although ORR and DCR were numerically higher in the WBRT+SIB group, these differences were not statistically significant. Given the limitations of this exploratory study, these findings should be considered hypothesis-generating and require validation in prospective randomized trials.
SN - 2072-6694
ER -